Pharmaceutical firm Lupin announced that it has received tentative approval from the US health regulator to market its generic version of Dolutegravir and Rilpivirine tablets used in treatment of HIV infection, in an exchange filing.
The tentative approval granted by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of Dolutegravir and Rilpivirine tablets of strength 50 mg/25 mg, Lupin said in the filing.
The Dolutegravir and Rilpivirine tablets, 50 mg/25 mg had estimated annual sales of USD 666 million in the US, the company said citing IQVIA MAT September 2022 data.
Bihar Final Electoral Rolls To Be Published On September 30: ECI
Uttarakhand CM Pushkar Singh Dhami Offers Prayers At Har Ki Pauri On Completing 4 Years In Office
Mira-Bhayandar News: Catholic Church Backs Dongri Protest Against Felling Of 10,000 Trees For Metro Line 9 Car Shed In Bhayandar
On Camera: Retired PWD Engineer Fires 5 Bullets At Stray Dog For Barking At Him In UP's Bijnor
